Welcome to
VeraSIL Therapeutic Research, Inc (“VeraSIL”)
This website describes a Program created by VeraSIL Therapeutics Research, Inc., (“VeraSIL”) which utilizes a novel Nanotechnology platform and government-funded Tax R&D initiatives (in both Canada and the USA) to not only improve patient outcomes but, the financial stability of a Dental practice/private healthcare facility.
VeraSIL was founded in 2014 by a group of Dental Healthcare Professionals to aid in the Research and Development of Dental specific applications for a novel NanoMetallic Silver Oxide technology – capable of providing broad-based antimicrobial activity combined with rapid improvements in wound healing and biofilm/smear layer reduction. Prior to the introduction of this technology platform, no such dual functioning antimicrobial – wound healing agents existed in the dental industry. As a result of these ongoing R&D efforts, a variety of proprietary clinical products and formulations were developed in an attempt to try and address challenges and Technological Uncertainties (“TUs”) which have remained unresolved and plagued the Dental Industry/Dentists for decades including:
- Pain
- Inflammation
- Infection
- Disinfection
- Wound Healing
- BioFilm
- Smear Layer
- Antibiotic Resistance
- Aerosol Generating Procedures
- Chemotoxic Ingredients
In 2018, VeraSIL’s focus shifted towards the development of hundreds of specific Clinical Protocols for a NanoMetallic Silver Oxide Technology called CURASIL® which could be used with a variety of other less chemo-toxic ingredients to help improve a wide range of clinical outcomes for dental patients.
Introducing, A Clinically Tested, Heavily Patented, NanoMetallic Silver Oxide Technology Called CuraSIL.
Providing Individually Formulated Products with the following superior properties:
- Anti-Inflammatory
- Pain reducing
- Potentiating / Synergistic with Antibiotics
- Helps eliminate Smear Layers & BioFilms
- Helps Eliminate Bacterial Resistance (3)
- Antimicrobial & Anti-Fungal benefits (4)
The result is an All Natural, Non-Chemotoxic, NanoMetallic Silver Oxide technology platform which can help to provide Improved Clinical Results and better Patient Outcomes…
(1) CuraSIL is a paradigm-shifting technology with the proven ability to fight Antibiotic Resistant bacteria such as MRSA, VRE and CRE.
(2) Readily mixed with varying concentrations and dilutions of adjuvants such as (EDTA, H202, Potassium Persulfate, Fluoride, IPA, BZK, Povidone Iodide, NaOCL, Aluminum Chloride & Medical Grade Enzymes).
(3) Hi Log reduction kills against MRSA, VRE, CRE, MDR Acinetobacter Baumanii and Candida albicans.
(4) Our NanoMetallic Silver particles are on average 5-7Nm in size.
Utilizing the CURASIL® Nanotechnology platform in combination with a diverse range of customizable clinical protocols, dosages, dilutions and ingredients (as well as less chemo-toxic formulations and improved delivery systems), VeraSIL has developed a Tax R&D eligible Program capable of addressing Technological Uncertainties (“TUs”) specific to the Dental industry. This Program allows Dentists to help improve clinical outcomes for their patients AND to file for much-needed tax relief in order to help financially support their dental businesses which has been ravaged by increased operational costs. The VeraSIL Program has helped to dramatically improve the Free Cash Flow / Profitability of many Professional Dental Corporations.
“The ONLY Technology Platform in the world which has the potential to legitimately address/resolve the issues of wound healing and disinfection as well as pain and inflammation in the Dental industry is Nanotechnology”. 2018 Newsletter, U.S National Institutes of Health (“USNIH”)
To date, we have not only developed hundreds of Proprietary Clinical Protocols to help address the above TUs but our R&D efforts have also resulted in a growing collection of evidence based medicine which points to the efficacy and performance of this NanoMetallic Silver technology including; Thousands of clinical based observations from Healthcare Professionals; Independent USP 51 21 CFR Part 58 Antimicrobial Tests against numerous pathogenetic microorganisms; Numerous independent public / third party studies and tests; Hundreds of Oral DNA Polymerase Chain Reaction (“PCR”) Salivary tests; Numerous whites papers; Peer reviewed and published papers; Multiple FDA cleared, IRB approved, randomized human clinical trials on the safety and efficacy of human ingestion of NanoMetallic Silver; PubMed research papers as well as the largest Peer reviewed Meta-Analysis on NanoSilver in Dentistry ever published, in an April 2017 issue of Dental Material’s Magazine by Nohrona et al.
Although R&D efforts are still ongoing, thus far, they have resulted in the development of numerous proprietary formulations and the issuance of more than twenty (20) US and Foreign Patents, (9) US and Canadian Registered Trademarks, as well as numerous Canadian and US regulatory clearances. Our latest Canadian Regulatory approval has come for our Super Hydrating Facial Serum which now has approved Antimicrobial and Wound Cleansing claims and for the treatment of Skin Affections including; seborrheic dermatitis, eczema, psoriasis and acne. With the addition of Hyaluronic Acid, Sonicated Nano-peptides and PBM Light Therapy, there is now Research into this potential ability help accelerate surgical wound closure/healing and bone remodelling as well as the possible effect on both the BONT’s time of onset and its duration of efficacy. These novel uses/applications/protocols are now the subject of extensive Patent Pending Applications and numerous R&D Projects.
For Further Information About The Science Of This NanoMetallic Silver Oxide Technology, Click The Button Below
ABOUT US
Our Goals are Three-Fold:
1. To be a leader in Dental Nanotechnology innovation by manufacturing and selling products that provide improved clinical outcomes for patients by delivering tangible value-added Antimicrobial, wound healing anti-inflammatory and pain-reducing benefits
2. To remove barriers b/w Dental Manufacturers and Dental Practitioners so as to provide new and improved Nanotechnology products and clinical techniques at significant cost savings.
3. To help Dentists utilize novel clinical products and protocols so that they can take advantage of long-standing Tax R&D Programs to help improve the Free Cash Flow and Profit of their Dental businesses.
What We Offer: An ever-expanding range of innovative NanoSilver-based dental products with the value-added clinical benefits of reduced infection rates, improved wound healing and reduced pain and inflammation. The ability to help train the Dental team on how to perform novel Tax R&D Activities using these NanoSilver products so that their business can participate in Tax R&D Programs which can help to improve the Free Cash Flow and Profit of the Dental business.
Our Value Added Proposition – Superior Price, Performance, Science and Value (“P.P.S.V.”) of a novel NanoMetallic Silver Oxide technology at a consistent wholesale price.
THE VeraSIL ADVANTAGE FOR THE DENTIST IS SIMPLE:
With a direct to Dentist model and local medical device manufacturing (cGMP) expertise, VeraSIL is able to provide value-added dental products to the Dental team with superior Antimicrobial, Anti-inflammatory and Wound healing benefits for the patient.
This breakthrough “CuraSIL” technology platform allows Dentists to better manage their patient’s post-operative pain, inflammation and disease – all at a much more reasonable price and in a much more consistent, predictable and reliable manner – all without the use of chemo-toxic ingredients.
SENIOR MANAGEMENT TEAM – VeraSIL’s Senior Management team has over 300 years of combined experience in the successful start-up, growth and sale of a diverse array of healthcare-related businesses. Attached are their abbreviated CV Bios.
Dr. Andrew Willoughby, DMD, LVIF, FICOI, FICCMO, FAGD, FAACFP, MICCMO. Founding Director and President of VeraSIL Therapeutics and is responsible for the implementation of its business model. Dr. Willoughby has over 10 years of experience as a dental lab technician and 35 years as a General Dentist. Andrew operates two full-time surgical/restorative-based general practices in British Columbia, Canada. Andrew holds 7 different clinical certifications and has extensive training in TMJ / Airway / CT Guided DI / GTR surgery and combined Tooth-Implant and Full Mouth Reconstructions. Andrew is the named Inventor of 90 US and Foreign Patents including the Priority dated Patents in the area of CAD/CAM Custom Milled Dental Implant Abutments which he licensed to Straumann Holdings, AG in June 2002. Dr. Willoughby has written numerous white papers, lectured internationally and was recently published in the prestigious Springer International Journal of Wound Healing. In 2018 Dr. Willoughby completed the very first double-length PBS Documentary Special on Guided Implant Dentistry which aired North America-wide, on more than 430 PBS Affiliate TV Stations over an 18-month period to a viewing audience in excess of 125 Million viewers. Dr Willoughby has been incorporating the use of a novel Antimicrobial Wound Healing NanoMetallic Silver Oxide technology into his clinical practice for over 17 years now and since 2018, Andrew has been utilizing Nanotechnology based Tax R&D Programs to not only improve patient clinical outcomes but to generate increased profitability and Free Cash Flow for his dental corporation. Dr Willoughby is currently working on numerous novel digital workflow programs for the manufacture of anatomically corrected multi-rooted dental implant fixtures and optical scanning componentry for milled and 3D printed post & cores. E> drandrewwilloughby@verasil.com
Mr. W. Brooks Pierce, LLB. Executive Vice President, Chief Operating Officer Chief Legal Officer. Mr. Pierce is an American attorney and business advisor with 25 years of legal and business experience based in Kansas City, Kansas. Brooks joined VeraSIL in 2020 as Executive Vice President overseeing all legal and licensing functions for the Company. Brooks’ day-to-day activities involve interfacing with our Tax R&D administrators and overseeing the implementation of all License & Supply Agreements with VeraSIL clients and structuring business arrangements with DSOs. Brooks has extensive experience in areas ranging from financial services, consumer products, tribal enterprises and cryptocurrency. His work has been both domestic and international, having worked extensively in Europe and the republics of the former Soviet Union. In the early to mid-2000s, Mr. Pierce was Associate General Counsel for NovaStar Financial, Inc. in Kansas City, Missouri a leader in the subprime mortgage lending industry. Earlier in his career, Mr. Pierce was a Vice President with the Industrial Bank of Japan-Whitehall in New York, New York and a Director with the Georgetown University School of Business in Washington, D.C. Mr. Pierce received his undergraduate degree from the University of Colorado and his law degree from the University of Kansas School of Law. E>brookspierce@verasil.com
Mr. Brent Chow, CPA. CFO. (bio to follow)
Mr. Pat Hanley, US Director of Sales. Pat attended Weaver State College/University, Ogden Utah from 1977-1980. Pat has spent the majority of his career working as a licensed stockbroker and investment consultant. In his 40+ year career, Pat has successfully raised in excess of 125 Million USD of capital for a range of private and now publicly traded companies and has been involved in at least 10 reverse mergers/public listings. As a series 7-63 broker his involvement (buying and selling stock on a daily basis) with Dauphin Technologies (DNTK) resulted in the most highly traded stock on the OTCBB between 1993-1997. Pat was first introduced to VeraSIL and Dr. Willoughby about 2 years ago, through one of VeraSIL’s manufacturers. Since this time, Pat has been instrumental in helping VeraSIL build a highly motivated sales team across the United States. As VeraSIL’s US Director of Sales, Pat’s primary focus is on managing VeraSIL’s growing sales force and facilitating conversations between small to medium DSOs and VeraSIL’s executive team. E>pathanley@verasil.com
John F. King: US Director of Marketing. John has enjoyed a decades-long career in the financial services industry as a Registered Representative (Stockbroker) for American Express Financial Advisors, a Sales and Marketing Representative at a Blue Cross Blue Shield organization, and the Managing Partner of LTCi Plans, LLC. He was responsible for the sales and service of national accounts including institutional members of academia, medicine, telecommunications, and aerospace (NASA/DOD) engineering. John is a national expert on extended healthcare planning and has provided state-certified continuing education for CPAs in his field. He was recruited to be the Executive Producer & Host of InsuranceRadio.com and has relished the opportunity to interview national leaders across the industry. John has undergraduate and graduate degrees from The University of Alabama (where his sons are currently studying Mechanical Engineering and Biology). Over the last 5 years, John has served as a business development consultant for fintech and biotech startup firms when he found the transformational technology and tax-reduction strategies at VeraSIL. John’s entire career has revolved around leveraging tax-qualified products to mitigate risk and improve patient outcomes, and so he is excited by the opportunity to help market and promote VeraSIL’s Nanotechnology-based Tax R&D Programs to healthcare professionals. John has been a consumer of this specific NanoMetallic Silver particle for several years and lives in Birmingham, Alabama with his wife and two sons. E> john.king@verasil.com
Mrs. Capri Rietel: Canadian Director of Sales. Graduate of Capilano University. From 2004- 2007 Capri was the BC Provincial Sales Manager for Virgin Mobile Canada who successfully managed almost 90 key retail accounts including Future Shop, Best Buy, London Drugs and Walmart. From 2007-2011 Capri has a key Account Manager for a number of large retail companies where she managed order fulfillment for accounts including Kruger Paper, United Rentals, National Car Rentals and various retail automotive and recreational vehicle accounts, From 2011-2013 Capri was the Key Accounts Manager for Acklands Grainger overseeing all sales functions for accounts such as Flynn Canada, Amtec, Atlas Copco Thiessen and Endurance Wind Power. From 2013-2017 Capri was president of Unite Social Media Services. Capri is the past Founder & President of CuraSIL Silver Technologies, Inc. which registered the original CuraSIL US and Cdn trademarks. In 2019, VeraSIL acquired the CuraSIL brand name and Company. Capri has been working closely with Dr. Willoughby and VeraSIL ever since. Capri is a long-standing patient of Dr. Willoughby’s and is very familiar with all the various NanoSilver protocols and the positive impacts they have on both patient outcomes and the dental practice. Capri has been conducting in-person training and helping onboard VeraSIL’s Canadian Dental clients since March 2020. E> capririetel@verasil.com
Dr. Leo Malin, DDS, LVIF, Implant Surgeon, Director of Online Clinical Training. Leo has been placing and restoring Dental Implants for more than 30 years. Dr. Malin is considered a world-leading authority on CT-guided implant planning/placement and fixture design and is one of the original advocates of the long-taper, conical-shaped, platform-shifting implant designs for which he has been issued several priority-dated US and Foreign Patents. Leo’s innovation and expertise have led to the development of Implant Logistics and the Implant One Dental Implant system, which is now utilized by Dentists throughout North America. Since 2012 Leo has been running an ADA CERP Program for Dental Implants in the Dominican Republic and will be overseeing all of VeraSILs online clinical training. Since 2017, Dr. Malin has been utilizing VeraSIL’s Nanotechnology-based Clinical Protocols for the surgical placement and prosthetic restoration of dental implants and is currently participating in Tax R&D activities with these same products. Dr. Malin is currently working on a revolutionary implant thread design (with a major Medical Orthopedic company) to radically improve the initial stability of the dental implant in soft, spongy bone at the time of placement. President & Founder, Implant Logistics & IST Seminars, & co-owner of AMS MicroMedical – an ISO 13485 Compliant Medical Device Manufacturer, Lacrosse, WI. E> malindds@gmail.com
Dr. Kevin Mudrow, DDS, Director of In-person Clinical Training. Senior Dental Clinician, South West Oregon US Gov., HHS Sponsored Community Care Program. Kevin has been practicing general Dentistry for over 16 years and has a true passion for laser-assisted, biomimetic general restorative dentistry. Dr. Mudrow has been using NanoMetallic Silver Oxide for the past 2+ years and is keenly interested in the oral microbiome and the negative impact that many commonly used chemo-toxic ingredients can have on gut health. Kevin has been working with and formulating this Nanotechnology with various formats of Sodium and Stannous Fluoride as an alternative to SDF as well as in combination with ingredients such as PreBiotics, Calcium Carbonate, EDTA, Potassium Oxalate and Hydrogen Peroxide in order to try and help reduce the incidence of plaque, biofilm, root caries and hypo calcification/decay in the dental practice. Dr Mudrow holds an advanced clinical certification with the BioLase laser and is one of only a handful of Dentists in the USA that has successfully integrated the use of the NanoMetallic Silver technology into every hard and soft tissue dental laser procedure. Drs Mudrow will be managing and performing all live clinical training for VeraSIL Dental Clients. E>kevinmudrow@yahoo.com
Dr. Charles Drury, Bsc., DDS, AEDG, FAGD, FIADFE, FICD, Sr. Clinical Consultant, completed his undergraduate degree at the University of California at Riverside with a B.S. in Psychobiology (Neuroscience). He completed an Emt-1 certification at UCLA. After earning a Doctor of Dental Surgery degree from the University of the Pacific School of Dentistry, he completed the Advanced Education in General Dentistry (AEGD) Postdoctoral Program, which is an intensive clinical and academically rigorous full-time 12-month certificate program. As a presenter, he has delivered well-received lectures to a range of audiences with a variety of expertise, from the American Academy of General Dentistry to the Women’s Health Organization. Currently, Dr. Drury serves in an advisory capacity to a number of boards, including Promethean Dental Systems; Revere Partners; Profit4Dentists.com, the University of Stetson (leadership and innovation); and Recordlinc where he has also helped design and create software. Charles has been recognized with awards from the U.S. Senate; U.S. House of Representatives; the California Legislative Assembly; and the Academy of General Dentistry. Charles serves as a Sr. Dental Clinical Consultant to VeraSIL Therapeutics and assists in onboarding and training Dental clients with various Nanotechnology related clinical protocols and educating Dentists on the benefits of Tax R&D. E> drcharlesdrury@verasil.com
Mr. Andy McClennan, US Director of Customer Integration Services (“C.I.S.”). Andy has over 23 years of experience in real estate sales as a custom home builder/designer, and general contractor. From 1999 – 2014, Andy owned a successful real estate business in Iowa where he completed a 40 Acre subdivision. Andy is a successful residential real estate developer/broker and has built over 100 high-end custom homes. Andy was first introduced to VeraSIL about 1.5 years ago when he started consuming these products for his own personal use. The VeraSIL products helped improve his own dental situation so dramatically that Andy started almost immediately promoting these products to Dentists throughout the Southwestern United States – acting as a VeraSIL sales representative. Andy has excelled at helping to onboard new Dental Clients and explaining the dual functionality of VeraSIL’s program – which enures to the benefit of both the patient and the dental practice. As Director of Customer Integration Services, Andy continues to help sign up Dental clients, arrange for their clinical training and help educate them on how to establish, track, monitor and manage their R&D activities. Andy is an avid hiker and golfer and lives in Arizona with his wife Tressa, 5 dogs, 1 cat and a pet tortoise. E>andrew.maclennan@verasil.com
Dr. Paul Milne, PhD (Org. Chem), MBA. Senior Regulatory Affairs Consultant and Canadian Tax R&D Administrator for VeraSIL. Paul is the President of Imperia Brand Strategies & Solutions and is responsible for Imperia’s science-related client services including natural health product review, product licensing, product reformulation, SR&ED tax credit recovery and general business consulting. Dr. Milne has 8 years of experience as a medicinal chemist. His research focused on the use of natural products (beta-amino acids) and derivatives for the treatment of neurodegenerative disorders including epilepsy, Alzheimer’s and stroke. The work resulted in numerous scientific publications, a triple patent (novel products, novel process, novel utility) and sizeable government and corporate funding. Dr. Milne also has 14 years of experience in the areas of venture creation, business assistance and technology commercialization. Dr. Milne has worked as a Research Associate for the National Research Council of Canada (NRC Ottawa) where he assisted with the commercialization of drug delivery technology applicable to anti-aging cosmetics, nutraceuticals for humans and companion animals, and anti-fungal pharmaceuticals. He also worked as an analyst for a community-based venture capital fund where he evaluated more than 50 business opportunities annually. Dr. Milne is also responsible for over 1% of all NPN Regulatory approvals in Canada and has successfully completed multiple Nanotechnology-related NPNs, DINs and cosmetic applications for VeraSIL. Paul has also been filing Tax R&D Applications since 1996 (27 years) and with VeraSIL clients for over 5 years now. E>phmpm@sympatico.ca
Mr. Rob Penz. Dir. of Contract Manufacturing & Supply Chain Mgmnt. Rob is the owner of Medtrica Solutions, Inc., located in Surrey, British Columbia, Canada. Medtrica is a world-class, NHPD site licensed, cGMP manufacturer of enzymatic solutions which currently formulates, manufactures, bottles, labels, packages, distributes and sells significant volumes of medical grade enzymes to MedLine Industries – one of the largest healthcare distributors in North America. Rob has over 20 years of contract manufacturing experience and is a partner in Direct Dental Source Manufacturing, Inc (‘DDSource”). Medtrica is the exclusive contract manufacturer for (“DDSource) and VeraSIL Therapeutics. All products produced under the CuraSIL, OraSIL, VeraSIL or Natura Dental brand names are manufactured, bottled and packaged for DDSource by Medtrica either in its Surrey, BC facilities or its US operations located in Los Angeles, CA. Rob Penz and Andrew Willoughby have been business partners for over 5 years. E> rpenz@medtrica.com
Mr. Sean Bystrom, Dip Eng. Dir. of Operations. Sean has an engineering background and is responsible for operating and maintaining a cGMP and NHPD Site licensed facility where he oversees and manages all aspects of the contract manufacturing (including mixing, formulating, bottling, labelling, packaging and inventorying) for the complete VeraSIL line of NanoMetallic Silver Oxide products.
Ms. Hang Tran: Manager, Order Fulfillment & Shipping. Hang is responsible for assembling all Product orders, preparing all customs documentation and paperwork for shipment to customers.
Ms. Cheryl Dyksorn: Manager, Accounting and Bookkeeping. Cheryl is responsible for the creation of All Pro-Forma Invoices, Bills of Sale and bookkeeping.
Ms. Cerra Gelz, Lead CDA & Surgical Assistant. Co-Director Staff Training. Cerra has been working closely with Dr. Willoughby for over 13 years as his lead CDA and Surgical Assistant. Cerra has advanced training in Neuromuscular / Physiologic Based Dentistry as well as all forms of Dental surgery from Connective Tissue Grafting, CT Guided Implant Placement, Sinus Lifts and Guided Tissue Regeneration using a variety of biological materials. In 2013 Cerra received her Orthodontic Module and ever since has been helping Dr. Willoughby implement Accelerated Tooth movements for both SWT and CAT patients utilizing novel clinical protocols involving the combined use of Low-Intensity Pulsed Ultrasound (“LIPUS”) and Nanotechnology. Cerra has also helped implement similar innovations with LIPUS and Sinus lifts as well as Osseous regeneration procedures to accelerate bone remodelling. Cerra helps track, record and compile the day-to-day R&D Activities in the Dental Office and explains these procedures to patients.
E> Cerragelz@verasil.com
Ms. Serena Collins, Executive Administrator & Co-Director Staff Training. Serena has been working with Dr. Willoughby for over 14 years as his Executive Administrator & Operations Manager. In this capacity, Serena is intimately familiar with how VeraSIL’s Tax R&D Program is implemented on a day-to-day basis. Ms. Collins helps Dr. Willoughby track and monitor all NanoSilver clinical protocols, materials consumed and materials transformed on his General Ledger and Daily treatment schedules and helps train the staff on everything related to NanoMetallic Silver. Serena is responsible for the processing of all VeraSIL Purchase Orders received from Dental/healthcare clients, customer invoicing and tracking AWBs for all customer orders. E> Serenacollins@verasil.com
ADVISORY BOARDS/MEMBERS
Financial & Legal Consultants:
Mr. Chris Katsanevas, B.Sc., CSE, CFP, Partner, Soulence Tax & Wealth Advisors
Mr. Chris Anderson, CPA, Partner, Soulence Tax & Wealth Advisors
Mr. Randall Richards LLB and Corporate Tax Attorney
Mr. Ridge Hartley, CFP, Securities & Insurance Broker
Business / Regulatory Consultants:
Mr. Timothy A Brown, CEO, ROI Corp Dental Brokerage
Dr Gerald Curatola, DDS, Biologic & Restorative Dentist, Author, Researcher and Humanitarian.
Dr. Graham Willoughby, DDS, MDS, Consultant
IP Consultants:
Mr. David D. McMasters, Patent & Trademark Attorney
Mr. David Parker, Patent & Trademark Attorney
Ms. Capri Reitel, Trademark Specialist.
Clinical Consultants (‘KOLs’). All of the following Clinicians have utilized VeraSIL’s Nanotechnology products and can attest to their Safety, Efficacy, Performance and Stability. Many of them have also developed their own unique NanoMetallic Silver Oxide Clinical Protocols.
To view our Clinical Advisors you will need to enter a valid User Name and Password.
ALL of VeraSIL’s products are manufactured exclusively by DDSource Manufacturing, INC., Unit101 – 3525 191 Street, Surrey British Columbia, Canada.